VHL and nonpapillary renal cell carcinoma: Figure 1B shows the viability in two different ccRCC primary tumors (ccRCC 4 and 7), the VHL−/− human RCC cell line 786-O, and the VHL+/+ Human Umbilical Vein Endothelial Cell (HUVECs) after treatment with different doses of propranolol or ICI for 72 h.